艾滋病相关卡波西肉瘤的局部卤泛酮 II 期艾滋病恶性肿瘤联合会试验。
Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.
机构信息
Ireland Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
出版信息
J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):64-8. doi: 10.1097/QAI.0b013e3181fc0141.
Abstract
Using a novel blinded intrapatient vehicle control design, we conducted a phase II study of topically administered halofuginone, an angiogenesis inhibitor that inhibits collagen type-I and matrix metalloproteinases (MMPs), in patients with AIDS-related Kaposi sarcoma. Serial Kaposi sarcoma biopsies assessed treatment effects on angiogenic factors and Kaposi sarcoma herpesvirus-latency associated nuclear antigen-1 (KSHV-LANA). We observed marked heterogeneity of KSHV-LANA expression. Although the small number of subjects whose response could be evaluated precluded definitive assessment of halofuginone's efficacy, we observed a significant decrease in type-I collagen only in halofuginone-treated lesions, but no effect on MMP-2. The trial design is applicable to future studies of topical agents.
摘要
采用新型盲法患者自身对照设计，我们开展了一项局部给予海夫定的 II 期研究，海夫定为血管生成抑制剂，可抑制 I 型胶原和基质金属蛋白酶（MMPs）。该研究入组了 AIDS 相关性卡波西肉瘤患者。对卡波西肉瘤活检标本进行连续检测，以评估血管生成因子和卡波西肉瘤疱疹病毒潜伏相关核抗原-1（KSHV-LANA）的治疗效果。我们观察到 KSHV-LANA 表达存在明显异质性。尽管可评估应答的受试者数量较少，无法明确评估海夫定的疗效，但我们仅观察到海夫定治疗病灶中 I 型胶原显著减少，但对 MMP-2 无影响。该试验设计适用于未来的局部药物研究。
相似文献
1
Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma.
J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):64-8. doi: 10.1097/QAI.0b013e3181fc0141.
2
Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma.
Clin Cancer Res. 2020 Feb 1;26(3):558-565. doi: 10.1158/1078-0432.CCR-19-1044. Epub 2019 Oct 17.
3
Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group.
J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):235-46. doi: 10.1097/00126334-199911010-00004.
4
Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial.
J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):149-53. doi: 10.1097/01.qai.0000194237.15831.23.
5
Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.
J Clin Oncol. 2014 Feb 10;32(5):402-8. doi: 10.1200/JCO.2012.48.6365. Epub 2013 Dec 30.
6
Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials.
Arch Dermatol. 2000 Dec;136(12):1461-9. doi: 10.1001/archderm.136.12.1461.
7
New drug targets in Kaposi sarcoma.
Expert Opin Ther Targets. 2010 Dec;14(12):1355-66. doi: 10.1517/14728222.2010.532336. Epub 2010 Nov 2.
8
Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium.
Cancer. 2008 Mar 1;112(5):1083-8. doi: 10.1002/cncr.23108.
9
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
J Clin Oncol. 2005 Feb 10;23(5):990-8. doi: 10.1200/JCO.2005.11.043. Epub 2004 Dec 14.
10
Gel approved for KS.
AIDS Patient Care STDS. 1999 May;13(5):309. doi: 10.1089/apc.1999.13.309.
引用本文的文献
1
Targeting collagen to optimize cancer immunotherapy.
Exp Hematol Oncol. 2025 Jul 29;14(1):101. doi: 10.1186/s40164-025-00691-y.
2
Traditional medicine meets modern science: Halofuginone's role in combating autoimmune diseases.
J Nat Med. 2025 Jun 30. doi: 10.1007/s11418-025-01927-1.
3
Halofuginone for non-hospitalized adult patients with COVID-19 a multicenter, randomized placebo-controlled phase 2 trial. The HALOS trial.
PLoS One. 2024 Feb 23;19(2):e0299197. doi: 10.1371/journal.pone.0299197. eCollection 2024.
4
Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl-tRNA synthetase 1.
EMBO Mol Med. 2023 Jul 10;15(7):e16940. doi: 10.15252/emmm.202216940. Epub 2023 May 22.
5
Metabolic reprogramming in cancer: Mechanisms and therapeutics.
MedComm (2020). 2023 Mar 27;4(2):e218. doi: 10.1002/mco2.218. eCollection 2023 Apr.
6
The KEAP1-NRF2 System and Esophageal Cancer.
Cancers (Basel). 2022 Sep 27;14(19):4702. doi: 10.3390/cancers14194702.
7
Topical treatments for Kaposi sarcoma: A systematic review.
Skin Health Dis. 2022 Apr 8;2(2):e107. doi: 10.1002/ski2.107. eCollection 2022 Jun.
8
Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on.
J Clin Oncol. 2022 Jan 20;40(3):294-306. doi: 10.1200/JCO.21.02040. Epub 2021 Dec 10.
9
Nanosecond pulsed electric fields induce the integrated stress response via reactive oxygen species-mediated heme-regulated inhibitor (HRI) activation.
PLoS One. 2020 Mar 10;15(3):e0229948. doi: 10.1371/journal.pone.0229948. eCollection 2020.
10
Cancer-Associated Fibroblasts Build and Secure the Tumor Microenvironment.
Front Cell Dev Biol. 2019 Apr 24;7:60. doi: 10.3389/fcell.2019.00060. eCollection 2019.
本文引用的文献
1
Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response.
Science. 2009 Jun 5;324(5932):1334-8. doi: 10.1126/science.1172638.
2
Kaposi's sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases.
J Virol. 2007 Jul;81(13):7001-10. doi: 10.1128/JVI.00016-07. Epub 2007 Apr 18.
3
Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling.
Cell Tissue Res. 2007 Apr;328(1):153-66. doi: 10.1007/s00441-006-0330-1. Epub 2006 Dec 19.
4
Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study.
J Clin Oncol. 2006 Mar 20;24(9):1389-94. doi: 10.1200/JCO.2005.04.2614.
5
Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
J Clin Oncol. 2005 Feb 10;23(5):982-9. doi: 10.1200/JCO.2005.06.079. Epub 2004 Nov 30.
6
Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of halofuginone in plasma.
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Oct 15;810(1):35-40. doi: 10.1016/j.jchromb.2004.07.010.
7
Smad3 as a mediator of the fibrotic response.
Int J Exp Pathol. 2004 Apr;85(2):47-64. doi: 10.1111/j.0959-9673.2004.00377.x.
8
Growth inhibition of prostate cancer xenografts by halofuginone.
Prostate. 2002 May 1;51(2):73-83. doi: 10.1002/pros.10059.
9
Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.
J Clin Oncol. 2002 Jan 1;20(1):153-9. doi: 10.1200/JCO.2002.20.1.153.
10
Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor.
Mol Biol Cell. 2001 Oct;12(10):2934-46. doi: 10.1091/mbc.12.10.2934.
Zotero 插件